» Articles » PMID: 36831421

Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin

Abstract

A second-line standard of treatment has not yet been identified in patients with soft tissue sarcomas (STS), so identifying predictive markers could be a valuable tool. Recent studies have shown that the intratumoral and inflammatory systems significantly influence tumor aggressiveness. We aimed to investigate prognostic values of pre-therapy neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic inflammatory index (SII), progression-free survival (PFS), and overall survival (OS) of STS patients receiving second-line treatment. In this single-center retrospective analysis, ninety-nine patients with STS were enrolled. All patients received second-line treatment after progressing to anthracycline. PFS and OS curves were calculated using the Kaplan-Meier method of RNA sequencing, and CIBERSORT analysis was performed on six surgical specimens of liposarcoma patients. A high NLR, PLR, and SII were significantly associated with worse PFS ( = 0.019; = 0.004; = 0.006). Low LMR was significantly associated with worse OS ( = 0.006). Patients treated with Trabectedin showed a better PFS when the LMR was low, while patients treated with other regimens showed a worse PFS when the LMR was low ( = 0.0154). The intratumoral immune infiltrates analysis seems to show a correlation between intratumoral macrophages and LMR. PS ECOG. The metastatic onset and tumor burden showed prognostic significance for PFS ( = 0.004; = 0.041; = 0.0086). According to the histologies, PFS was: 5.7 mo in liposarcoma patients vs. 3.8 mo in leiomyosarcoma patients vs. 3.1 months in patients with other histologies ( = 0.053). Our results confirm the prognostic role of systemic inflammatory markers in patients with STS. Moreover, we demonstrated that LMR is a specific predictor of Trabectedin efficacy and could be useful in daily clinical practice. We also highlighted a possible correlation between LMR levels and the percentage of intratumoral macrophages.

Citing Articles

Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.

Rodrigues-Santos P, Almeida J, Sousa L, Couceiro P, Martinho A, Rodrigues J Front Immunol. 2025; 16:1516793.

PMID: 40007535 PMC: 11850243. DOI: 10.3389/fimmu.2025.1516793.


Prognostic Value of Inflammatory and Nutritional Indicators in Non-Metastatic Soft Tissue Sarcomas.

Yan Y, Zhang Y, Chen Y, Zhong G, Huang W, Zhang Y J Inflamm Res. 2025; 18:1941-1950.

PMID: 39959645 PMC: 11827485. DOI: 10.2147/JIR.S501079.


Systemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin.

Sobczuk P, Filipowicz P, Lamparski L, Kosela-Paterczyk H, Teterycz P, Kozak K Sci Rep. 2025; 15(1):5247.

PMID: 39939795 PMC: 11821830. DOI: 10.1038/s41598-025-89977-z.


Bibliometric analysis of liposarcomas treatment from 2004 to 2023.

Wang X, Ye J, Liu D, Yan L, Li S, Lv A J Cancer Res Clin Oncol. 2025; 151(2):47.

PMID: 39856436 PMC: 11762222. DOI: 10.1007/s00432-025-06094-0.


Comprehensive analysis of prognostic and immunological role of basement membrane-related genes in soft tissue sarcoma.

Nie G, Liu C, Tian Z Immun Inflamm Dis. 2024; 12(10):e70037.

PMID: 39392257 PMC: 11467964. DOI: 10.1002/iid3.70037.


References
1.
Chen S, Luo P, Yang L, Zheng B, Sun Z, Yan W . Prognostic analysis of surgically treated clear cell sarcoma: an analysis of a rare tumor from a single center. Int J Clin Oncol. 2019; 24(12):1605-1611. PMC: 6861539. DOI: 10.1007/s10147-019-01487-x. View

2.
Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J . The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2013; 135(2):362-70. DOI: 10.1002/ijc.28677. View

3.
Luo P, Cai W, Yang L, Chen S, Wu Z, Chen Y . Prognostic significance of pretreatment lymphocyte/monocyte ratio in retroperitoneal liposarcoma patients after radical resection. Cancer Manag Res. 2018; 10:4727-4734. PMC: 6201845. DOI: 10.2147/CMAR.S171602. View

4.
Verma S, Younus J, Stys-Norman D, Haynes A, Blackstein M . Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008; 34(4):339-47. DOI: 10.1016/j.ctrv.2008.01.005. View

5.
De Larco J, Wuertz B, Furcht L . The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004; 10(15):4895-900. DOI: 10.1158/1078-0432.CCR-03-0760. View